These studies may partly account for the effects of PIM-1 on pancreatic cancer but do not explain the mechanisms by which PIM-1 regulates the sensitivity of cells to erlotinib or affects the expression of pancreatic cancer stem cell markers. This evidence concerns the gene PIM1 and pancreatic neoplasm.